Clin Mol Hepatol > Volume 30(2); 2024 > Article
Jang: Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”
Dear Editor,
I am grateful to Xie and his colleagues for providing additional new results to my editorial comments. The authors showed that junctional protein associated with coronary artery disease (JCAD) and YAP were positive in CK-19-positive cells known as bile duct epithelial cells (BECs) in newly formed bile ducts through immunohistochemical staining in liver tissue of primary biliary cholangitis patients [1]. This result suggests that high expression of JCAD in reactive bile duct epithelial cells may be involved in the proliferative response of BECs. Additionally, although the authors did not show the results, they found co-localization of F-actin and JCAD in the bile canaliculi of the regenerative mouse liver, suggesting that JCAD may function as a binding protein important in forming tight junctions between hepatocytes. However, it is difficult to accurately determine its function simply by the level of expression in the tissue, so additional research will be needed to determine the role of JCAD expression in BECs in the future. The role of JCAD expression in hepatocytes was well demonstrated in a recently published paper by the authors. In a partial hepatectomy mouse model, JCAD deficiency was shown to cause delayed liver regeneration through the Hippo-Yap signaling pathway [2]. Taken together, these results suggest that JCAD is expressed in various cells present in the liver and is involved in chronic injury and repair processes. However, on the one hand, increased expression of JCAD promotes the regeneration of hepatocytes and bile duct epithelial cells [1,2]. but also promotes the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma and activates hepatic stellate cells in cholestatic liver disease [3,4]. However, since most diseases progress through an overlap of injury and repair, there are concerns that it may require more work to apply it directly for therapeutic purposes. Therefore, through further research on these issues in the future, we hope to accumulate knowledge about the mechanism and role of JCAD in various liver diseases and apply it to treatment.

FOOTNOTES

Conflicts of Interest
The authors have no conflicts to disclose.

Abbreviations

JCAD
junctional protein associated with coronary artery disease
YAP
Yes-associated protein
BECs
bile epithelial cells

REFERENCES

1. Xie L, Zhang L, Chen H, Yang YY, Wu J. Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances. Clin Mol Hepatol 2024;30:279-280.
crossref pmid pdf
2. Zhang L, Yang YY, Xie L, Zhou Y, Zhong Z, Ding J, et al. JCAD deficiency delayed liver regenerative repair through the HippoYAP signalling pathway. Clin Transl Med 2024;14:e1630.
crossref pmid pmc
3. Ye J, Li TS, Xu G, Zhao YM, Zhang NP, Fan J, et al. JCAD Promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. Cancer Res 2017;77:5287-5300.
crossref pmid pdf
4. Xie L, Chen H, Zhang L, Ma Y, Zhou Y, Yang YY, et al. JCAD Deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis. Clin Mol Hepatol 2024;30:206-224.
crossref pmid pdf

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1800
TOTAL : 1776725
Close layer